Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity
A panel of experts examines the impact of cardiometabolic diseases in the United States, focusing on their burden, prevalence, and relationship to obesity.
Now Viewing
EP: 1.The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity
EP: 2.Strategies for Prevention and Screening of CRM Conditions
EP: 3.The Link Between Obesity and CRM Conditions
EP: 4.Challenges in Managing Co-Morbid CRM Conditions
EP: 5.Contemporary Guidelines for CRM Conditions
EP: 6.Reasons for Low Adherence to Guidelines for CRM Conditions
EP: 7.Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
EP: 8.Educational Initiatives to Enhance Guideline Adherence in CRM
EP: 9.Addressing Gaps in CKD, T2D, and CVD Guidelines
EP: 10.Care Coordination for High-Risk CRM Patients
EP: 11.Takeaways from the UH CINEMA Program
EP: 12.Exploring the Kidney-CHAMP Study
EP: 13.Insights from the COORDINATE-Diabetes Trial
EP: 14.Coordinating Initiatives to Enhance CRM Care
EP: 15.Implementing CRM Learnings and Utilization of Telehealth
Video content above is prompted by the following:
- What is the clinical and economic burden of Cardiorenal Metabolic Disease (CRM) conditions such as type 2 diabetes, chronic kidney disease, cardiovascular disease and heart failure in the United States?
- How do CRM conditions affect patient quality of life and clinical outcomes?
- How do these conditions impact healthcare resource utilization?
- The CDC has announced that over 42% of adults have obesity; what role does obesity play in the prevalence of CRM conditions in the United States?
- Is this your experience in your practice?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Related Videos
Related Content
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025Article
In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
